Literature DB >> 29486580

The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families.

Marjo Eveliina Hiekkala1, Pietari Vuola1,2, Ville Artto2, Paavo Häppölä3, Elisa Häppölä1, Salli Vepsäläinen2, Ester Cuenca-León4,5, Dennis Lal5,6,7,8, Padhraig Gormley5,6,9,10, Eija Hämäläinen3, Matti Ilmavirta11, Markku Nissilä12, Erkki Säkö13, Marja-Liisa Sumelahti14, Hanna Harno15, Hannele Havanka16, Petra Keski-Säntti17, Markus Färkkilä2, Aarno Palotie3,4,5,6,7,9,10, Maija Wessman1,3, Mari Anneli Kaunisto3, Mikko Kallela2.   

Abstract

Objective To study the position of hemiplegic migraine in the clinical spectrum of migraine with aura and to reveal the importance of CACNA1A, ATP1A2 and SCN1A in the development of hemiplegic migraine in Finnish migraine families. Methods The International Classification of Headache Disorders 3rd edition criteria were used to determine clinical characteristics and occurrence of hemiplegic migraine, based on detailed questionnaires, in a Finnish migraine family collection consisting of 9087 subjects. Involvement of CACNA1A, ATP1A2 and SCN1A was studied using whole exome sequencing data from 293 patients with hemiplegic migraine. Results Overall, hemiplegic migraine patients reported clinically more severe headache and aura episodes than non-hemiplegic migraine with aura patients. We identified two mutations, c.1816G>A (p.Ala606Thr) and c.1148G>A (p.Arg383His), in ATP1A2 and one mutation, c.1994C>T (p.Thr665Met) in CACNA1A. Conclusions The results highlight hemiplegic migraine as a clinically and genetically heterogeneous disease. Hemiplegic migraine patients do not form a clearly separate group with distinct symptoms, but rather have an extreme phenotype in the migraine with aura continuum. We have shown that mutations in CACNA1A, ATP1A2 and SCN1A are not the major cause of the disease in Finnish hemiplegic migraine patients, suggesting that there are additional genetic factors contributing to the phenotype.

Entities:  

Keywords:  ICHD-3 beta criteria; Migraine with aura; clinical characteristics; exome sequencing; ion channel; pathogenic variant

Mesh:

Substances:

Year:  2018        PMID: 29486580     DOI: 10.1177/0333102418761041

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  11 in total

1.  Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families.

Authors:  Padhraig Gormley; Mitja I Kurki; Marjo Eveliina Hiekkala; Kumar Veerapen; Paavo Häppölä; Adele A Mitchell; Dennis Lal; Priit Palta; Ida Surakka; Mari Anneli Kaunisto; Eija Hämäläinen; Salli Vepsäläinen; Hannele Havanka; Hanna Harno; Matti Ilmavirta; Markku Nissilä; Erkki Säkö; Marja-Liisa Sumelahti; Jarmo Liukkonen; Matti Sillanpää; Liisa Metsähonkala; Seppo Koskinen; Terho Lehtimäki; Olli Raitakari; Minna Männikkö; Caroline Ran; Andrea Carmine Belin; Pekka Jousilahti; Verneri Anttila; Veikko Salomaa; Ville Artto; Markus Färkkilä; Heiko Runz; Mark J Daly; Benjamin M Neale; Samuli Ripatti; Mikko Kallela; Maija Wessman; Aarno Palotie
Journal:  Neuron       Date:  2018-05-03       Impact factor: 17.173

2.  Familial hemiplegic migraine in a child with seizure disorder: clinical history is the key to diagnosis.

Authors:  Pranav Balakrishnan; Phalguna Kousika Katakam; Asha P Hegde
Journal:  BMJ Case Rep       Date:  2019-03-25

Review 3.  Migraine.

Authors:  Michel D Ferrari; Peter J Goadsby; Rami Burstein; Tobias Kurth; Cenk Ayata; Andrew Charles; Messoud Ashina; Arn M J M van den Maagdenberg; David W Dodick
Journal:  Nat Rev Dis Primers       Date:  2022-01-13       Impact factor: 52.329

Review 4.  Epilepsy and Migraine Shared Genetic and Molecular Mechanisms: Focus on Therapeutic Strategies.

Authors:  Palvi Gotra; Nidhi Bhardwaj; Abhilash Ludhiadch; Gagandeep Singh; Anjana Munshi
Journal:  Mol Neurobiol       Date:  2021-04-15       Impact factor: 5.590

5.  Correlations of Calcium Voltage-Gated Channel Subunit Alpha1 A (CACNA1A) Gene Polymorphisms with Benign Paroxysmal Positional Vertigo.

Authors:  Ruichun Pan; Xiaokun Qi; Fei Wang; Yi Chong; Xia Li; Qiang Chen
Journal:  Med Sci Monit       Date:  2019-02-02

6.  First Attack and Clinical Presentation of Hemiplegic Migraine in Pediatric Age: A Multicenter Retrospective Study and Literature Review.

Authors:  Irene Toldo; Francesco Brunello; Veronica Morao; Egle Perissinotto; Massimiliano Valeriani; Dario Pruna; Elisabetta Tozzi; Filomena Moscano; Giovanni Farello; Roberto Frusciante; Marco Carotenuto; Carlo Lisotto; Silvia Ruffatti; Ferdinando Maggioni; Cristiano Termine; Gabriella Di Rosa; Margherita Nosadini; Stefano Sartori; Pier Antonio Battistella
Journal:  Front Neurol       Date:  2019-10-15       Impact factor: 4.003

Review 7.  Exploring the Hereditary Nature of Migraine.

Authors:  Charlene Bron; Heidi G Sutherland; Lyn R Griffiths
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-22       Impact factor: 2.570

8.  Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.

Authors:  Paavo Häppölä; Padhraig Gormley; Marjo E Nuottamo; Ville Artto; Marja-Liisa Sumelahti; Markku Nissilä; Petra Keski-Säntti; Matti Ilmavirta; Mari A Kaunisto; Eija I Hämäläinen; Samuli Ripatti; Matti Pirinen; Maija Wessman; Aarno Palotie; Mikko Kallela
Journal:  Cephalalgia       Date:  2021-10-14       Impact factor: 6.292

9.  Comprehensive Exonic Sequencing of Hemiplegic Migraine-Related Genes in a Cohort of Suspected Probands Identifies Known and Potential Pathogenic Variants.

Authors:  Heidi G Sutherland; Neven Maksemous; Cassie L Albury; Omar Ibrahim; Robert A Smith; Rod A Lea; Larisa M Haupt; Bronwyn Jenkins; Benjamin Tsang; Lyn R Griffiths
Journal:  Cells       Date:  2020-10-28       Impact factor: 6.600

Review 10.  A Systematic Review of Extreme Phenotype Strategies to Search for Rare Variants in Genetic Studies of Complex Disorders.

Authors:  Sana Amanat; Teresa Requena; Jose Antonio Lopez-Escamez
Journal:  Genes (Basel)       Date:  2020-08-25       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.